NCT06442267View on ClinicalTrials.gov

Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

PHASE4RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

January 30, 2027

Study Completion Date

July 30, 2027

Conditions
Respiratory InsufficiencyCirculatory FailureThromboembolismBleeding
Interventions
DRUG

Enoxaparin Injectable Solution

Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily

DRUG

Argatroban, 1 Mg/mL Intravenous Solution

Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.

DRUG

Unfractionated heparin

Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.

Trial Locations (1)

1090

RECRUITING

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER